Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2023 Earnings Presentation
16 slides from Laboratorio Reig Jofre's earnings presentation, February 2024
Slide 1: 4Q 2023 Results
4Q 2023 RESULTS PHARMA SECTOR reigjofre.com
Slide 2: Disclaimer
DISCLAIMER This presentation does not contain any confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is provided in summary form and does not purport to be complete. The information contained in this pr
Slide 3: Table of Contents
TABLE OF CONTENTS → 4Q 2023 RESULTS → INCOME STATEMENT AND BALANCE SHEET → PERFORMANCE OF RJF SHARE 3
Slide 4: 4Q 2023 Results
RESULTS YY) ian) C aN CY wT
Slide 5: Reig Jofre's revenues grow 17% and its EBITDA 15%
4Q 2023 RESULTS Reig Jofre’s revenues grow 17% and its EBITDA 15% ▪ Sales in 2023 reached 316 million euros, 17% higher than in 2022, the highest growth in SALES recent years. The medical products division, Speciality Pharmacare, leads this growth, followed by Pharmaceutical Technologies and Consume
Slide 6: Revenues by Business Units
REVENUES BY BUSINESS UNITS SALES 2023 €316 M +17% PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC / Energy / Stress and sleep Injectables / Lyophilised Dermatology / Weight control / Beauty 44 € 138.7M % +11% 33% €105.1M +31% 23% €72.3M +10% Glob
Slide 7: International Developments
INTERNATIONAL DEVELOPMENTS Rest of Rest of TOTAL PRESENCE SALES 2023 SPAIN EUROPE WORLD All business units are growing at double-digit rates, with notable expansion osteoarticular product range, increased in +70 COUNTRIES €316 M 45% €141.1 M 43% €137.7 M 12% €37.3 M manufacturing capacity for inje
Slide 8: Income Statement and Balance Sheet
INCOME STATEMENT AND BALANCE SHEET
Slide 9: Income Statement
INCOME STATEMENT EVOLUTION 2023 / 2022 V% ▪ Revenues increased by 17%, with an associated gross margin thousand euros 31/12/2023 31/12/2022 of 58%, matching the 2022 margin despite cost increases, Turnover 316.088 271.150 17% especially in antibiotics. Procurements -140.454 -114.138 Changes in inven
Slide 10: Balance Sheet: Assets and Investments
BALANCE SHEET INVESTMENT 2023 ASSETS AND INVESTMENTS 2023 €12.5 M thousand euros 31/12/2023 31/12/2022 INDUSTRIAL CAPEX ASSETS Goodwill 27.985 28.972 10,6 M Other intangible assets 63.070 70.893 Property, plant and equipment 91.625 93.192 Investments in equity-accounted investees 4.600 3.541 R&D ACT
Slide 11: Balance Sheet: Liabilities and Debt
BALANCE SHEET INVESTMENT 2023 LIABILITIES AND DEBT 2023 NET FINANCIAL DEBT DEBT / EBITDA close of close of thousand euros 31/12/2023 31/12/2022 2023 €55.8 M 2023 1.6x close of close of EQUITY AND LIABILITIES 2022 €64.2 M 2022 2.0x TOTAL EQUITY 204.254 194.553 Capital grants 3.571 3.695 Provisions 19
Slide 12: Performance of RJF Share
PERFORMANCE OF RJF SHARE 12
Slide 13: Performance of Shares and Market Capitalisation
PERFORMANCE OF SHARES VALUATION €2.25 +3% 29/12/2023 MARKET Daily average 2023 CAPITALISATION VALUATION €2.51 VOLUME 9,415 shares CASH €23.7 K €179 M CASH AND AVERAGE DAILY VALUATION 50.000 € 2,7 € 29/12/2023 45.000 € 40.000 € 2,6 € 35.000 € 2,5 € 30.000 € 25.000 € 2,4 € SHAREHOLDER COMPOSITION 20.0
Slide 14: Save the Date
SAVE THE DATE PRESENTATION OF 2023 RESULTS AND 2024 OUTLOOK 13 March 2024 - 9:30 am Palacio de la Bolsa de Madrid Plaza de la Lealtad 1, Madrid. WEBCAST live in English/Spanish Access at www.reigjofre.com 14
Slide 15: Links and Additional Information
LINKS AND ADDITIONAL INFORMATION → RESULTS WEBCAST https://reigjofre.com/en/investors/webcasts/ https://reigjofre.com/en/investors/presentations/ → SUBSCRIPTION CENTRE https://reigjofre.com/en/news/subscription-center/ → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre.com/en/oth
Slide 16: Thank You
4Q 2023 THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com